MAManar Alkuzweny

Manar Alkuzweny

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manar Alkuzweny has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Refining uncertainty about the TAK-003 dengue vaccine with a multi-level model of clinical efficacy trial data

    by Manar Alkuzweny, Guido España, T Alex Perkins

    Background A safe and effective vaccine that can be universally administered would represent a major advance in efforts to control dengue. Takeda’s TAK-003 is a potential candidate for such a vaccine. However, phase-III trial results suggest that TAK-003 confers differential protection by outcome, serotype, and serostatus. Published analyses estimated these stratified vaccine efficacies independently, ignoring the fact that some aspects of the disease process are shared across particular stratifications. Methods We addressed these shortcomings by building a multi-level model that pooled all publicly available trial data to estimate parameters that characterize this vaccine’s profile. Results We found that protection varied by both serotype and serostatus, with initial protection against symptomatic disease ranging from a median of 99.6% (95% credible interval [CrI]: 96.5, 100.0) among seronegatives infected with DENV-2 to 26.7% (95% CrI: −8.2, 54.9) among seronegatives infected with DENV-3. We found that initial protection against hospitalized disease among those with symptomatic disease ranged from 98.7% (95% CrI: 90.1, 100.0) among seropositives infected with DENV-2 to −72.7% (95% CrI: −149.4, −4.0) among seronegatives infected with DENV-3. Importantly, our estimate of the latter is less uncertain than a previously published efficacy estimate (−87.9%, 95% CI: −573.4, 47.6). Conclusions Our results demonstrate that inferences based on complex data from a clinical trial can be sensitive to model structure. Additionally, they reinforce the recommendation from the World Health Organization that use of this vaccine is best suited to high-transmission settings.

  • Open Access

    Refining uncertainty about the TAK-003 dengue vaccine with a multi-level model of clinical efficacy trial data

    by Manar Alkuzweny, Guido España, T. Alex Perkins

    Background: A safe and effective vaccine that can be universally administered would represent a major advance in efforts to control dengue. Takeda’s TAK-003 is a potential candidate for such a vaccine. However, phase-III trial results suggest that TAK-003 confers differential protection by outcome, serotype, and serostatus. Published analyses estimated these stratified vaccine efficacies independently, ignoring the fact that some aspects of the disease process are shared across particular stratifications. Methods: We addressed these shortcomings by building a multi-level model that pooled all publicly available trial data to estimate parameters that characterize this vaccine’s profile. Results: We found that protection varied by both serotype and serostatus, with initial protection against symptomatic disease ranging from a median of 99.6% (95% credible interval [CrI]: 96.5, 100.0) among seronegatives infected with DENV-2 to 26.7% (95% CrI: −8.2, 54.9) among seronegatives infected with DENV-3. We found that initial protection against hospitalized disease among those with symptomatic disease ranged from 98.7% (95% CrI: 90.1, 100.0) among seropositives infected with DENV-2 to −72.7% (95% CrI: −149.4, −4.0) among seronegatives infected with DENV-3. Importantly, our estimate of the latter is less uncertain than a previously published efficacy estimate (−87.9%, 95% CI: −573.4, 47.6). Conclusions: Our results demonstrate that inferences based on complex data from a clinical trial can be sensitive to model structure. Additionally, they reinforce the recommendation from the World Health Organization that use of this vaccine is best suited to high-transmission settings.

  • Top Cited Papers
    Open Access

    Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations

    by Karthik Gangavarapu, Alaa Abdel Latif, Julia L. Mullen, Manar Alkuzweny, Emory Hufbauer, Ginger Tsueng, Emily Haag, Mark Zeller, Christine M. Aceves, Karina Zaiets, et al.

    In response to the emergence of SARS-CoV-2 variants of concern, the global scientific community, through unprecedented effort, has sequenced and shared over 11 million genomes through GISAID, as of May 2022. This extraordinarily high sampling rate provides a unique opportunity to track the evolution of the virus in near real-time. Here, we present outbreak.info, a platform that currently tracks over 40 million combinations of Pango lineages and individual mutations, across over 7,000 locations, to provide insights for researchers, public health officials and the general public. We describe the interpretable visualizations available in our web application, the pipelines that enable the scalable ingestion of heterogeneous sources of SARS-CoV-2 variant data and the server infrastructure that enables widespread data dissemination via a high-performance API that can be accessed using an R package. We show how outbreak.info can be used for genomic surveillance and as a hypothesis-generation tool to understand the ongoing pandemic at varying geographic and temporal scales.


  • Top Cited Papers

    Outbreak.info Research Library: a standardized, searchable platform to discover and explore COVID-19 resources

    by Ginger Tsueng, Julia L. Mullen, Manar Alkuzweny, Marco Cano, Benjamin Rush, Emily Haag, Jason Lin, Dylan J. Welzel, Xinghua Zhou, Zhongchao Qian, et al.

    Outbreak.info Research Library is a standardized, searchable interface of coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) publications, clinical trials, datasets, protocols and other resources, built with a reusable framework. We developed a rigorous schema to enforce consistency across different sources and resource types and linked related resources. Researchers can quickly search the latest research across data repositories, regardless of resource type or repository location, via a search interface, public application programming interface (API) and R package.


  • Open Access

    Outbreak.info Research Library: A standardized, searchable platform to discover and explore COVID-19 resources

    by Ginger Tsueng, Julia L. Mullen, Manar Alkuzweny, Marco Cano, Benjamin Rush, Emily Haag, Outbreak Curators, Jason Lin, Dylan J. Welzel, Xinghua Zhou, et al.

    To combat the ongoing COVID-19 pandemic, scientists have been conducting research at breakneck speeds, producing over 52,000 peer-reviewed articles within the first year. To address the challenge in tracking the vast amount of new research located in separate repositories, we developed outbreak.info Research Library, a standardized, searchable interface of COVID-19 and SARS-CoV-2 resources. Unifying metadata from sixteen repositories, we assembled a collection of over 350,000 publications, clinical trials, datasets, protocols, and other resources as of October 2022. We used a rigorous schema to enforce consistency across different sources and resource types and linked related resources. Researchers can quickly search the latest research across data repositories, regardless of resource type or repository location, via a search interface, public API, and R package. Finally, we discuss the challenges inherent in combining metadata from scattered and heterogeneous resources and provide recommendations to streamline this process to aid scientific research.


  • Open Access

    Ignoring transmission dynamics leads to underestimation of the impact of a novel intervention against mosquito-borne disease

    by Sean Cavany, John Huber, Annaliese Wieler, Tran Minh Quan, Manar Alkuzweny, Margaret Elliot, Guido España, Sean Moore Moore, T. Perkins

    New vector-control technologies to fight mosquito-borne diseases are urgently needed, the adoption of which depends on efficacy estimates from large-scale cluster-randomized trials (CRTs). The release of Wolbachia-infected mosquitoes is one promising strategy to curb dengue virus (DENV) transmission, and a recent CRT reported impressive reductions in dengue incidence following the release of these mosquitoes. Such trials can be affected by multiple sources of bias, however. We used mathematical models of DENV transmission during a CRT of Wolbachia-infected mosquitoes to explore three such biases: human movement, mosquito movement, and coupled transmission dynamics between trial arms. We show that failure to account for each of these biases would lead to underestimated efficacy, and that the majority of this underestimation is due to the bias caused by transmission coupling. We also find that the extent of bias is heightened when the spatial scale of clusters is small, or when the intervention is less efficacious. Taken together, our findings suggest that this intervention could be even more promising than the recent CRT suggested. By emphasizing the importance of accounting for transmission coupling between arms, which requires a mathematical model, our results highlight the key role that such models can play in interpreting and extrapolating the results from trials of vector control interventions.

  • Open Access

    Outbreak.info Research Library: A standardized, searchable platform to discover and explore COVID-19 resources

    by Laura Hughes, Ginger Tsueng, Julia Mullen, Manar Alkuzweny, Marco Cano, Benjamin Rush, Emily Haag, Alaa Abdel Latif, Xinghua Zhou, Zhongchao Qian, et al.

    To combat the ongoing COVID-19 pandemic, scientists have been conducting research at breakneck speeds, producing over 52,000 peer-reviewed articles within the first year. To address the challenge in tracking the vast amount of new research located in separate repositories, we developed outbreak.info Research Library, a standardized, searchable interface of COVID-19 and SARS-CoV-2 resources. Unifying metadata from fourteen repositories, we assembled a collection of over 270,000 publications, clinical trials, datasets, protocols, and other resources as of May 2022. We used a rigorous schema to enforce consistency across different sources and resource types and linked related resources. Researchers can quickly search the latest research across data repositories, regardless of resource type or repository location, via a search interface, public API, and R package. Finally, we discuss the challenges inherent in combining metadata from scattered and heterogeneous resources and provide recommendations to streamline this process to aid scientific research.

  • Open Access

    Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations

    by Laura Hughes, Karthik Gangavarapu, Alaa Abdel Latif, Julia Mullen, Manar Alkuzweny, Emory Hufbauer, Ginger Tsueng, Emily Haag, Mark Zeller, Christine Aceves, et al.

    The emergence of SARS-CoV-2 variants of concern has prompted the need for near real-time genomic surveillance to inform public health interventions. In response to this need, the global scientific community, through unprecedented effort, has sequenced and shared over 11 million genomes through GISAID, as of May 2022. This extraordinarily high sampling rate provides a unique opportunity to track the evolution of the virus in near real-time. Here, we present outbreak.info, a platform that currently tracks over 40 million combinations of PANGO lineages and individual mutations, across over 7,000 locations, to provide insights for researchers, public health officials, and the general public. We describe the interpretable and opinionated visualizations in the variant and location focussed reports available in our web application, the pipelines that enable the scalable ingestion of heterogeneous sources of SARS-CoV-2 variant data, and the server infrastructure that enables widespread data dissemination via a high performance API that can be accessed using an R package. We present a case study that illustrates how outbreak.info can be used for genomic surveillance and as a hypothesis generation tool to understand the ongoing pandemic at varying geographic and temporal scales. With an emphasis on scalability, interactivity, interpretability, and reusability, outbreak.info provides a template to enable genomic surveillance at a global and localized scale.


  • Open Access

    Ignoring transmission dynamics leads to underestimation of the impact of a novel intervention against mosquito-borne disease

    by Sean M. Cavany, John H. Huber, Annaliese Wieler, Quan Minh Tran, Manar Alkuzweny, Margaret Elliott, Guido España, Sean M. Moore, T. Alex Perkins

    New vector-control technologies to fight mosquito-borne diseases are urgently needed, the adoption of which depends on efficacy estimates from large-scale cluster-randomized trials (CRTs). The release of Wolbachia -infected mosquitoes is one promising strategy to curb dengue virus (DENV) transmission, and a recent CRT reported impressive reductions in dengue incidence following the release of these mosquitoes. Such trials can be affected by multiple sources of bias, however. We used mathematical models of DENV transmission during a CRT of Wolbachia -infected mosquitoes to explore three such biases: human movement, mosquito movement, and coupled transmission dynamics between trial arms. We show that failure to account for each of these biases would lead to underestimated efficacy, and that the majority of this underestimation is due to a heretofore unrecognized bias caused by transmission coupling. Taken together, our findings suggest that Wolbachia -infected mosquitoes could be even more promising than the recent CRT suggested. By emphasizing the importance of accounting for transmission coupling between arms, which requires a mathematical model, our results highlight the key role that models can play in interpreting and extrapolating the results from trials of vector control interventions.